The offer is there for us to help however we can, but you would need to provide us with the information we would need for our help to be effective.
Scott Brunner of the Alliance for Pharmacy Compounding has described this as the start of a "protracted process." Even under the most optimistic scenario, broad clinical availability of legally compounded versions of these peptides is likely a mid-to-late 2026 proposition at the earliest and possibly longer if the political or regulatory environment shifts
Potential areas of scientific interest include: Interaction with signaling pathways involved in tissue physiology Influence on vascular-related biological mechanisms Engagement with molecular processes associated with cellular response Individual responses may vary, and outcomes are not guaranteed
BPC-157 has no approved therapeutic indication in humans and is not recognized as a medicine, supplement, or drug by Health Canada
Most foam dissipates during this time
Tirzepatide (Mounjaro/Zepbound) for weight management and glycemic control